103 results
8-K
EX-1.1
NRIX
Nurix Therapeutics Inc
12 Apr 24
Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering
5:12pm
and shall be responsible for making its own independent investigation and appraisal of the transactions contemplated hereby, and neither … .
(s) Independent Accountants. PricewaterhouseCoopers LLP, which has certified certain financial statements of the Company and its subsidiaries
8-K
EX-5.1
NRIX
Nurix Therapeutics Inc
12 Apr 24
Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering
5:12pm
Certificate”). We have not undertaken any independent investigation to verify the accuracy of any such information, representations or warranties
424B5
NRIX
Nurix Therapeutics Inc
12 Apr 24
Prospectus supplement for primary offering
5:10pm
in reliance on the report of PricewaterhouseCoopers LLP, an independent registered public accounting firm, given on the authority of said firm … , commission or agency fees or other items constituting underwriting compensation to be received by any FINRA member or independent broker-dealer shall
424B5
NRIX
Nurix Therapeutics Inc
11 Apr 24
Prospectus supplement for primary offering
4:06pm
ended November 30, 2023 have been so incorporated in reliance on the report of PricewaterhouseCoopers LLP, an independent registered public accounting … by any FINRA member or independent broker-dealer shall be fair and reasonable. We may enter into agreements to indemnify underwriters, dealers and agents
S-8
EX-5.1
ujsd vott6pd8ipy
15 Feb 24
Registration of securities for employees
4:51pm
S-8
tvnc 0tpd88
15 Feb 24
Registration of securities for employees
4:51pm
S-8
EX-23.1
y8dz ocehcy14n
15 Feb 24
Registration of securities for employees
4:51pm
8-K
EX-99.1
vg8vr7i1sl
8 Jan 24
Regulation FD Disclosure
7:03am
8-K
EX-99.1
do4na1r
13 Nov 23
Regulation FD Disclosure
7:01am
8-K
at6fho40w6f2w
4 May 23
Submission of Matters to a Vote of Security Holders
4:09pm